Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study.
mTOR inhibitors avoid calcineurin nephrotoxicity, but sirolimus de novo is associated with unacceptable side effects and higher rejection rates. We have investigated a modified strategy: alemtuzumab induction with tacrolimus and mycophenolate maintenance, switching from tacrolimus to sirolimus at 6...
Κύριοι συγγραφείς: | Sutherland, A, Akhtar, M, Zilvetti, M, Brockmann, J, Ruse, S, Fuggle, S, Sinha, S, Harden, P, Friend, P |
---|---|
Μορφή: | Conference item |
Έκδοση: |
2014
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression.
ανά: Flechner, S, κ.ά.
Έκδοση: (2005) -
Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression.
ανά: Trzonkowski, P, κ.ά.
Έκδοση: (2008) -
ALEMTUZUMAB INDUCTION IN PANCREAS TRANSPLANTATION
ανά: Muthusamy, A, κ.ά.
Έκδοση: (2011) -
Systematic reviews of alemtuzumab in renal transplantation.
ανά: O'Callaghan, J, κ.ά.
Έκδοση: (2013) -
Systematic reviews of alemtuzumab in renal transplantation
ανά: O'Callaghan, J, κ.ά.
Έκδοση: (2013)